Isolation, expansion, transduction, and production of endothelial-cord derived working cell bank and blood stem cell transplantation final product in support of phase I-III clinical trials in malignancy
Confirming Feeder Cells for TIL Expansion Are Suitable for Phase II Clinical Trials and Beyond
Standard NH₄Cl erythroreduction protocols significantly impair T cell metabolic fitness and phosphorylation (30-40% reduction) despite normal viability metrics, revealing critical blind spots in current cell therapy quality control.
Tn/scm memory content varies dramatically across healthy donors and decreases non-linearly with age, while standard expansion protocols further reduce these critical cells essential for durable therapeutic responses.
Excellos offers free 60-minute CMC strategy consultations for early-stage cell therapy developers, addressing critical regulatory and manufacturing decisions before they become costly bottlenecks in IND filings and clinical timelines.d